Wilbraham, MA – July 22, 2016 – FloDesign Sonics announced today the addition of Kevin S. Delbridge to their Board of Directors. FloDesign Sonic's CEO, Stanley Kowalski III expressed his delight with Kevin's role in the company's evolution: "Kevin led our Series A1 round and has agreed to join our board, a significant milestone in our corporate history. Kevin has substantial background in providing strategic leadership to some of the world's most influential boards and venture funds, and I am delighted to have him as a mentor for our team."
Kevin's addition to the FloDesign Sonics team strengthens the company's roots in the local Massachusetts community and positions the company to broaden its scope. Delbridge explains: "I have known Stan and the founding team for over 10 years now. Having served as Chairman of the Board of Trustees at Western New England University and witnessed firsthand the birth of groundbreaking technology in Dr. Bart Lipkens' campus laboratory, I have great pride in both my alma mater and in FloDesign Sonics. I am super excited and have rolled up my sleeves."
Investors and board members John and Steve Davis from Ventry Industries are just as excited. John said, "Kevin was raised in Springfield, MA and shares our vision of bringing high paying jobs back to Western MA." Steve adds, "Kevin's roots in the region and enthusiasm for both the technology and enormous market opportunity make him a perfect match for us."
In addition to providing guidance, expertise, and funding to FloDesign Sonics, Delbridge's new role marks an important transition for the company. Investor and board member Jim Waters elaborates: "FloDesign Sonics has transitioned from an R&D company to a product company, and Kevin is uniquely qualified to guide our growth to a billion-dollar valuation. He thinks really, really big!"
Co-Founder and CTO of FloDesign Sonics, Dr. Bart Lipkens puts Kevin's role in context: "We launched our first product for Cell Clarification with Pall Corp at Interphex this past April. It's exciting to see our technology transition from the laboratory at Western New England University to the booth of the world's largest filter company within a few short years."
FloDesign Sonics closed a $10M Series A round in April of 2014 and has also been awarded grants from both the NSF and NIH totaling over $2M. In March 2016, FloDesign Sonics presented their technology at the White House Water Summit. The company plans to use the funding from the Series A1 to expand their processing solutions to enable cutting-edge cell and gene therapies. FloDesign Sonics plans to launch their first cell and gene therapy product at Interphex next year.
Stan Kowalski thanked Kevin for joining the board and highlighted his team's accomplishments: "We continue to do well by doing good. For example, our customers are developing game changing cell therapies for the treatment of cancer and heart diseases. The bottleneck is the cost of these drugs, averaging $100,000-$250,000 USD per patient. FloDesign Sonics will enable pharmaceutical companies to process their delicate cells at substantially lower cost, allowing these lifesaving therapies to reach more people at significantly lower costs."
About Kevin S. Delbridge
Kevin Delbridge has honed his investment strategies and expertise, developed commercial real estate, and tirelessly worked in philanthropic endeavors in the arts and education, all benefitting his New England community. From his leadership roles at Cigna Investments to his founding and leadership of HarbourVest Partners from a $2B fund to a $37B fund. Delbridge has established a track record of sourcing and directing successful investments, both international and domestic. With a BSBA from Western New England University and an MBA from University of Massachusetts, Delbridge demonstrates his commitment to his community by serving as Chairman of the Board of Trustees at Western New England University and on the Board of Governors at Tufts Medical Center.
About FloDesign Sonics
FloDesign Sonics is revolutionizing the separation, filtration and diagnostic markets through a novel acoustic technology. By leveraging breakthroughs in the use of multi-dimensional acoustic standing waves, FloDesign Sonics is able to capture, separate and purify mixtures and solutions without using physical membranes, chemicals, or centrifugation. Their proprietary technology has numerous applications in a variety of markets including life sciences, oil and gas, food and beverage and industrial processing. The first commercial application is in bioprocess separations, where FloDesign Sonics is applying acoustic technology to the manufacturing of life saving bio-pharmaceuticals.